ASX Biotech/Company Directory

/

descriptionAnnouncements scienceTrials warningRisk Matrix bookmarkWatchlist feedbackFeedback settingsSettings

RADRadiopharm Theranostics

data caveat$50M10mo

Companies/RAD

RADActiveTier 1Delivery · 2/2

Radiopharm Theranostics

Biotech · Radiopharmaceuticals

Radiopharmaceutical portfolio including RAD 204 (PSMA) and RAD 302 (NTR1)

Website ↗ASX ↗

Data HealthTrials4 of 7 active · stale enrollment

Cash data from Dec 2025 4CFigures from ASX filings · not financial advice

[ VITALS ]

Cash on Hand

$34.5M

Dec 2025 4C

Runway

10moCAUTION

Based on Dec 2025 4C

Market Cap

$50M

Burn Rate

$10.7M/qtr

Dec 2025 4C

Shares Outstanding

2.4B

Pipeline Assets

RAD

Latest Insight(1)

6 Apr 2026

PartnershipRAD and Siemens Sign Clinical Supply Agreement for RAD101

Siemens Healthineers·supply·United States

picture_as_pdfView full announcement

3M Price

RAD.ASX

$0.021-8.7% 3M

Low $0.019High $0.023

Pipeline Assets (1)

RAD 204Prostate cancer PSMA theranostics

Phase 1

Discovery

Preclinical

Ph 1

Ph 1/2

Ph 2

Ph 2/3

Ph 3

NDA

Approved

RAD 204

Prostate cancer PSMA theranostics

Capital Raises & Buybacks

show_chart

No capital raise or buyback data

Director Transactions

4 transactions

Last 90dNet Buy

Buys2+2 vs prior

Sells0-1 vs prior

Buy Value$28k

BUYIan Turneropen_in_new

730,000 sh@ $0.019$13,8702026-03-25

1d before · RAD 402 (RAD 402 Phase 1 Clinical Study) — RAD Doses First Patient in RAD 402 Phase 1 Clinical Study

BUY

Director Options & Rights

Director

Outstanding

Ex. Price

Expiry

No option data entered yet

Short Interest

ASIC ↗as of 2026-03-27 · 4-day lag

Short position

0.07%

arrow_drop_up+0.07% over 30 reports

Shares short

2.5M

Aggregated short position data published by ASIC under the Corporations Act. T+4 reporting lag applies. Short interest ≥5% is noteworthy; ≥10% is elevated. Source: ASIC Short Selling Data

Competitive Landscape

4 competitor trialsPhase 2+ · Non-ASX

Prostate Cancer Psma Theranostics4 active trials

1 Ph23 Ph1/PHASE2

Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.

Catalysts (12)· 6 upcoming · 6 past

RAD202 Phase 1 HEAT Trial Dose Escalation Completionopen_in_new

Upcoming

Expectedarrow_upwardHigh31 Dec 2026

PHASE1 data readout — A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Aopen_in_new

Upcoming

SpeculativeremoveMed30 Aug 2027

PHASE1/PHASE2 data readout — 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperableopen_in_new

Delivery Consistency Index

Historical delivery and spending consistency — data is limited for recently added companies.

Delivery Consistency Index

Delivery

–Insufficient data

2/3 data points needed

Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts

Capital discipline

–Insufficient data

1/2 data points needed

Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus

Hit 2 of 2 guided dates· rolling 2yr(limited sample)· of 12 tracked

Filed 1 of 1 4Cs on time· statutory deadline

Completed catalysts

✓RAD Completes Enrollment in Phase 2b Trial of RAD 101· readout — subject to clinical uncertainty— Enrollment of 30 patients has been completed in the U.S. multicenter Phase 2b trial. Interim data to date demonstrated 90% concordance with MRI, which is the primary endpoint of the study. Full clinical trial readout is expected in June 2026, with plans to advance into a U.S. Phase 3 pivotal trial thereafter.

On time

✓RAD Initial Findings from Phase 1 177Lu-RAD202 Trial· readout — subject to clinical uncertainty— 177Lu-RAD202 demonstrated meaningful tumor uptake at the lowest dose level of 30 mCi, particularly in breast cancer lesions, in a heavily pre-treated patient population. The drug was generally well tolerated with predominantly Grade 1-2 treatment-emergent adverse events and no dose-limiting toxicities or treatment discontinuations. The Data Safety and Monitoring Committee approved advancement to the third cohort at 130 mCi, supporting continued dose escalation.

On time

Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.

These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.

Clinical Trials(7)

7 activeClinicalTrials.gov ↗

Early Ph1RecruitingEnrollment stale · 688d

177Lu-RAD204

177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors

PDL1 Gene Mutation · Non Small Cell Lung Cancer · Small Cell Lung Cancer ( SCLC ) +6 more

18 Years+

Primary endpoint Time Activity Curves (TACs)

NCT06305962 ↗CT.gov

Start

2024-06

Primary end

2027-12

Early Ph1RecruitingEnrollment stale · 434d

177Lu-RAD202

HEAT Trial (HER2 Antibody Therapy With Lutetium-177)

HER2 Gene Mutation · Advanced Solid Tumors

18 Years+

Primary endpoint Time Activity Curves (TACs)

NCT06824155 ↗CT.gov

Start

2025-02

Primary end

2027-12

Ph1RecruitingEnrollment stale · 895d

RAD301 ([68Ga]-RAD301)

Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors

Healthy Volunteers · Pancreatic Ductal Adenocarcinoma · Non-small Cell Lung Cancer (NSCLC) +4 more

18 Years+

Primary endpoint Radiation dosimetry of RAD301

NCT05799274 ↗CT.gov

Start

2023-11

Primary end

2026-03

Announcements(11)

All announcements →

science

Trial Results

RAD Initial Findings from Phase 1 177Lu-RAD202 Trial

19 Apr 2026

131KB

science

Trial ResultsPS

RAD Completes Enrollment in Phase 2b Trial of RAD 101

15 Apr 2026

346KB

science

Trial ResultsPS

RAD202 Phase 1 HEAT Trial Advances to Dose Level 3

7 Apr 2026

127KB

handshake

Partnershipauto_awesome

RAD and Siemens Sign Clinical Supply Agreement for RAD101

6 Apr 2026

113KB

expand_more

person

Insider Tradeauto_awesome

Change of Director's Interest Notice (IT)

31 Mar 2026

218KB

expand_more

expand_more6 past catalysts

RAD101 2nd interim Ph.2b data - 90% achieve primary endpointopen_in_new

Completed

ConfirmedremoveMed23 Mar 2026

90% (18/20) of patients dosed with RAD101 achieved concordance between PET imaging and MRI, meeting the primary endpoint. Results showed significant and selective tumor uptake in brain metastases, confirming metabolic activity compared to equivocal MRI findings. The first five patients with six-month follow-up and/or biopsy data also showed a positive trend for sensitivity and specificity (secondary objectives).

RAD 402 (RAD 402 Phase 1 Clinical Study) — RAD Doses First Patient in RAD 402 Phase 1 Clinical Studyopen_in_new

Completed

ConfirmedremoveMed26 Mar 2026

Radiopharm Theranostics dosed the first patient in its first-in-human Phase 1 clinical trial of RAD 402, a monoclonal antibody targeting KLK3 radiolabelled with Terbium 161 for advanced prostate cancer. The dose escalation study is designed to determine the Maximum Tolerated Dose and recommended Phase 2 dose.

RAD202 Phase 1 HEAT Trial Advances to Dose Level 3open_in_new

Completed

ConfirmedremoveMed7 Apr 2026

The Data Safety and Monitoring Committee (DSMC) issued a positive recommendation to advance the trial from Cohort 2 (75mCi) to Cohort 3 (130mCi), indicating a favorable safety profile at previous dose levels. The company remains on track to complete Phase 1 dose escalation by end of 2026. A prior diagnostic study in ten HER2-positive breast cancer patients demonstrated clinical proof-of-concept with positive safety and biodistribution.

RAD202 Phase 1 HEAT Trial Advances to Dose Level 3open_in_new

Completed

ConfirmedremoveMed7 Apr 2026

The Data Safety and Monitoring Committee (DSMC) issued a positive recommendation to advance the HEAT trial from Cohort 2 (75mCi) to Cohort 3 (130mCi), indicating a favorable safety profile at lower dose levels. The dose escalation is progressing rapidly, with the company on track to complete Phase 1 dose escalation by end of 2026. The trial is currently being conducted at clinical centers across Australia.

RAD Completes Enrollment in Phase 2b Trial of RAD 101open_in_new

Completed

ConfirmedremoveMed15 Apr 2026

Enrollment of 30 patients has been completed in the U.S. multicenter Phase 2b trial. Interim data to date demonstrated 90% concordance with MRI, which is the primary endpoint of the study. Full clinical trial readout is expected in June 2026, with plans to advance into a U.S. Phase 3 pivotal trial thereafter.

RAD Initial Findings from Phase 1 177Lu-RAD202 Trialopen_in_new

Completed

ConfirmedremoveMed19 Apr 2026

177Lu-RAD202 demonstrated meaningful tumor uptake at the lowest dose level of 30 mCi, particularly in breast cancer lesions, in a heavily pre-treated patient population. The drug was generally well tolerated with predominantly Grade 1-2 treatment-emergent adverse events and no dose-limiting toxicities or treatment discontinuations. The Data Safety and Monitoring Committee approved advancement to the third cohort at 130 mCi, supporting continued dose escalation.

Event	Type	Confidence	Impact	Date	Status
RAD202 Phase 1 HEAT Trial Dose Escalation Completionopen_in_new The company is on track to complete Phase 1 dose escalation of the 177Lu-RAD202 HEAT trial by end of 2026. [Source: RAD202 Phase 1 HEAT Trial Advances to Dose Level 3, 2026-04-07]	data readout	Expected	arrow_upwardHigh	31 Dec 2026	Upcoming
PHASE1 data readout — A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Aopen_in_new Primary completion expected for NCT07272642. Indication: {Imaging,"Colorectal Cancer","Head and Neck Squamous Cell Carcinoma","Non-Small Cell Lung Cancer","Triple Negative Breast Cancer (TNBC)"}	data readout	Speculative	removeMed	30 Aug 2027	Upcoming
PHASE1/PHASE2 data readout — 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperableopen_in_new Primary completion expected for NCT07189871. Indication: {"Castration-Resistant Prostate Cancer (CRPC)","Colorectal Cancer","NSCLC (Non-small Cell Lung Cancer)","Ovarian Cancer","Cervical Cancer","Endometrial Cancer","TNBC, Triple Negative Breast Cancer","Small Cell Lung Cancer (SCLC )","Head &Amp; Neck Squamous Cell Carcinoma (HNSCC)","Esophageal Squamous Cell Carcinoma (ESCC)"}	data readout	Speculative	removeMed	1 Dec 2027	Upcoming
EARLY_PHASE1 data readout — 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumorsopen_in_new Primary completion expected for NCT06305962. Indication: {"PDL1 Gene Mutation","Non Small Cell Lung Cancer","Small Cell Lung Cancer ( SCLC )","TNBC, Triple Negative Breast Cancer","Cutaneous Melanoma",HNSCC,"Endometrial Cancer","Mmr Deficiency",MSI-High}	data readout	Speculative	removeMed	1 Dec 2027	Upcoming
EARLY_PHASE1 data readout — HEAT Trial (HER2 Antibody Therapy With Lutetium-177)open_in_new Primary completion expected for NCT06824155. Indication: {"HER2 Gene Mutation","Advanced Solid Tumors"}	data readout	Speculative	removeMed	1 Dec 2027	Upcoming
PHASE1/PHASE2 data readout — A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPCopen_in_new Primary completion expected for NCT07259213. Indication: {"Castration-resistant Prostate Cancer"}	data readout	Speculative	removeMed	30 Nov 2028	Upcoming

expand_more6 past catalysts

RAD101 2nd interim Ph.2b data - 90% achieve primary endpointopen_in_new 90% (18/20) of patients dosed with RAD101 achieved concordance between PET imaging and MRI, meeting the primary endpoint. Results showed significant and selective tumor uptake in brain metastases, confirming metabolic activity compared to equivocal MRI findings. The first five patients with six-month follow-up and/or biopsy data also showed a positive trend for sensitivity and specificity (secondary objectives).	data readout	Confirmed	removeMed	23 Mar 2026	Completed
RAD 402 (RAD 402 Phase 1 Clinical Study) — RAD Doses First Patient in RAD 402 Phase 1 Clinical Studyopen_in_new Radiopharm Theranostics dosed the first patient in its first-in-human Phase 1 clinical trial of RAD 402, a monoclonal antibody targeting KLK3 radiolabelled with Terbium 161 for advanced prostate cancer. The dose escalation study is designed to determine the Maximum Tolerated Dose and recommended Phase 2 dose.	other

Radiopharm Theranostics

Latest Insight(1)

3M Price

Pipeline Assets (1)

Capital Raises & Buybacks

Director Transactions

Director Options & Rights

Short Interest

Competitive Landscape

Catalysts (12)· 6 upcoming · 6 past

Delivery Consistency Index

Clinical Trials(7)

Announcements(11)

Quarterly Cash Flow